MedTrace Logo

Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes

NCT01536639 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 454

Last updated 2017-01-09

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of the study was to evaluate the safety and efficacy of biphasic insulin aspart 30 (NovoMix® 30) when switching to a modern premix insulin analogue treatment compared to previous insulin regimen in routine clinical practice in the Slovak Republic.

Conditions

Interventions

DRUG

biphasic insulin aspart 30

Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • Slovakia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01536639 on ClinicalTrials.gov